Date	Title	View
January 10, 2022	Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)
January 10, 2022	Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference